"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 5 | 0 | 5 |
| 1997 | 7 | 1 | 8 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 6 | 4 | 10 |
| 2001 | 12 | 0 | 12 |
| 2002 | 2 | 2 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 4 | 2 | 6 |
| 2005 | 7 | 1 | 8 |
| 2006 | 7 | 1 | 8 |
| 2007 | 8 | 2 | 10 |
| 2008 | 12 | 5 | 17 |
| 2009 | 18 | 2 | 20 |
| 2010 | 13 | 3 | 16 |
| 2011 | 19 | 2 | 21 |
| 2012 | 23 | 5 | 28 |
| 2013 | 14 | 2 | 16 |
| 2014 | 24 | 4 | 28 |
| 2015 | 27 | 1 | 28 |
| 2016 | 23 | 3 | 26 |
| 2017 | 20 | 1 | 21 |
| 2018 | 20 | 3 | 23 |
| 2019 | 32 | 5 | 37 |
| 2020 | 14 | 1 | 15 |
| 2021 | 30 | 1 | 31 |
| 2022 | 23 | 1 | 24 |
| 2023 | 31 | 0 | 31 |
| 2024 | 14 | 3 | 17 |
| 2025 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer. Clin Cancer Res. 2025 Jun 03; 31(11):2230-2240.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
-
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
-
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31; 613:217505.
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
-
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
-
Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium. Br J Cancer. 2025 Mar; 132(4):361-370.
-
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600.